Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Inovio’s Zika Vaccine Enters Early Clinical Trials

XTALKS VITALS NEWS

Mosquito

The Zika vaccine candidate is the first to be approved to enter clinical trials by the US Food and Drug Administration (FDA).

Share this!

June 22, 2016 | by Sarah Massey, M.Sc.

Inovio Pharmaceuticals plans to start a Phase I clinical trial of its experimental Zika vaccine in the next few weeks. The Zika vaccine candidate is the first to be approved to enter clinical trials by the US Food and Drug Administration (FDA).

The vaccine – dubbed GLS-5700 – is being jointly developed by Pennsylvania-based Inovio pharmaceuticals and South Korea-based GeneOne Life Science. The proposed Phase I clinical trial will involve 40 healthy volunteers to test the safety and of the vaccine as well as the immune response it elicits.

Tweet: The first #Zika vaccine study in human volunteers http://ctt.ec/ri6nd+

“We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers,” said Dr. J. Joseph Kim, Inovio’s President & CEO. “As of May 2016, 58 countries and territories reported continuing mosquito-borne transmission of the Zika virus; the incidences of viral infection and medical conditions caused by the virus are expanding, not contracting. We plan to dose our first subjects in the next weeks and expect to report Phase I interim results later this year.”

According to Inovio, preclinical results for the Zika vaccine have been promising. In both small and large animal models, the experimental vaccine was capable of inducing strong antibody and T cell responses.



The Zika virus – which is spread by a mosquito vector – has been associated with severe birth defects in infants, including microcephaly. According to a recent report from the Centers for Disease Control and Prevention (CDC), the epidemic has now spread to Puerto Rico, with over 1,700 cases of the disease identified there so far.

Though the virus has yet to spread to the Southern US states, the CDC has reported that three babies born with birth defects in the US have been linked to cases of the Zika virus contracted in endemic areas.

Other drugmakers, including vaccines giant Sanofi, have Zika vaccine candidates in the pipeline, however their clinical trials are not expected to commence until 2017 at the earliest. Despite Inovio’s success so far, it could be years before their Zika vaccine completes all stages of the clinical trials process and is granted regulatory approval.


Keywords: Zika, Vaccine, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News


PTC to Acquire Marathon’s Recently Approved Duchenne Muscular Dystrophy Drug

March 17, 2017 - Amid a drug pricing controversy, PTC Therapeutics has agreed to buy Marathon Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug, Emflaza.

Featured In: Pharmaceutical News


Memphis Meats Produces World’s First Poultry from Animal Cells

March 17, 2017 - Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.